Sign in
Taking peoplePhase 2

GenSci048 compared with placebo for active non-infectious uveitis

Tests GenSci048 against placebo in adults with active non-infectious uveitis.

Key facts

Who runs it
Changchun GeneScience Pharmaceutical Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis.
Status
Recruiting
Phase
Phase 2
People taking part
74 people, planned
Started
29 Jun 2026
Expected to end
13 Jan 2028
Type of study
Interventional, 2 groups
Treatments tested
  • GenSci048
  • Placebo
Record updated
24 July 2026

Who can take part

The trial is looking for adults with active non-infectious uveitis (eye inflammation not caused by infection) while taking oral prednisone. It compares GenSci048 with placebo.

Age
18 years and older.
Sex
All sexes can join.
Disease stage
Active non-infectious intermediate, posterior or pan-uveitis, first diagnosed more than 1 year ago. Disease must be active at the start visit.
Earlier treatment
People must be on a stable dose of oral prednisone for at least 2 weeks. They must have responded well before to oral corticosteroids (up to 1 mg/kg/day prednisone or equivalent). No anti-TNF or other biologic therapy for uveitis within 12 weeks before the start visit (anti-VEGF eye injections are allowed).
Main reasons for not taking part
  • Uveitis only in the front of the eye (isolated anterior uveitis).
  • Wet age-related macular degeneration, serious diabetic eye disease, or diabetic macular swelling.
  • Other inflammatory diseases needing ongoing oral corticosteroids or banned immune-suppressing drugs.
  • Confirmed active tuberculosis (TB).
  • Serious other illnesses, such as uncontrolled blood pressure (≥200/105 mmHg), Stage D heart failure, or uncontrolled diabetes.
Show the full registry criteria (12)Hide the full registry criteria

Who can take part

  • Age ≥18 years, regardless of gender
  • Diagnosed with non-infectious intermediate-, posterior-, or pan-uveitis, and had a medical history of more than 1 yearsince the initial diagnosis
  • Must have active disease at the baseline visit while receiving a stable dose of oral prednisone maintenance therapy for at least 2 weeks
  • Must have demonstrated a prior adequate response to oral corticosteroid therapy (equivalent of oral prednisone up to 1 mg/kg/day), as judged by the investigator
  • No intention to become pregnant and willingness to use highly effective contraception during the study and for 24 weeks after the last dose of study drug
  • Able to understand the study procedures, voluntarily agree to participate, provide written informed consent (ICF), and comply with study requirements and complete the study

Who cannot take part

  • Subjects with systemic inflammatory diseases requiring continued treatment with oral corticosteroids or prohibited immunosuppressive agents at screening or baseline visits
  • Subject has previous exposure to anti-tumor necrosis factor (TNF) therapy or any other biologic therapy with a potential therapeutic impact on non-infectious uveitis (intravitreal anti-VEGF therapy excluded) within 12 weeks prior to baseline visit
  • Any of the following:; Confirmed active tuberculosis (TB) infection, including but not limited to radiologically confirmed active TB; Subjects with latent TB infection or at high risk for TB may be enrolled, provided they are not considered unsuitable by the investigator (e.g., unwillingness to continue anti-TB treatment per local guidelines after entering the study)
  • Presence of significant comorbidities, including but not limited to: uncontrolled hypertension (≥200/105 mmHg), congestive heart failure (Stage D), or uncontrolled type 1 or type 2 diabetes (fasting blood glucose >7.0 mmol/L or random blood glucose >11.1 mmol/L); eligibility will be determined at the discretion of the investigator
  • Subjects with neovascular/wet age-related macular degeneration, proliferative or severe non-proliferative diabetic retinopathy, or clinically significant macular edema due to diabetic retinopathy
  • Subjects with isolated anterior uveitis

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Uveitis

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is designed to evaluate the efficacy and safety of GenSci048 compared with placebo in subjects with active non-infectious uveitis.

The 2 groups in the trial

  • GenSci048 groupTreatment being tested

    GenSci048 high-dose administered subcutaneously (SC) according to the protocol.

    Treatment: GenSci048

  • PlaceboTreatment being tested

    Administered SC every 4 weeks.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase II Clinical Study to Assess the Efficacy and Safety of GenSci048 in Subjects With Active Non-infectious Uveitis.
Plain-language title
GenSci048 compared with placebo for active non-infectious uveitisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07547995, who can take part
Record updated
24 July 2026